心脏移植患者环孢素A药动学研究

Pharmacokinetics of Cyclosporine A in Heart Transplant Recipients

目的荧光偏振免疫法测定心脏移植患者连续服用环孢素A至稳态后的血药浓度并考查其药动学特点。方法采用荧光偏振免疫法测定5名心脏移植术后患者服药达稳态后单剂量po环孢素A每次100mg,bid后药物在体内的经时过程。结果5名心脏移植术后患者环孢素A的tmax为（1.60±0.55）h ρmax为（951.60±229.20）μg·L-1,t1/2为（6.53±2.40）h,AUC0~t为（5162.10±1355.01）μg·h·L-1。结论建立中国心脏移植患者环孢素A的稳态药动学参数。

OBJECTIVE To determine the steady state concentration and the pharmacokinetics of cyclosporine A in the heart transplant recipients. METHODS A single dose of 100 mg CsA capsules twice daily was given to 5 heart transplant recipients of steady state. The concentrations of cyclosporine A in plasma were determined by SP-FPIA. RESULTS The main pharmacokinetic parameters of cyclosporine A were as follows： tma（1.60±0.55）h ρmax为（951.60±229.20）μg·L-1,t1/2（6.53±2.40）h,AUC0~t为（5162.10±1355.01）μg·h·L-1,respectively. CONCLUSION The study obtained the steady state pharmacokinetic parameters of CsA in Chinese heart transplant recipients.